Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment

2019 ◽  
Vol 234 (9) ◽  
pp. 14721-14733 ◽  
Author(s):  
Maryam Ebrahimi Nik ◽  
Amir Abbas Momtazi‐Borojeni ◽  
Parvin Zamani ◽  
Jamshid Gholizadeh Navashenaq ◽  
Mehrdad Iranshahi ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Metastatic Cancer ◽  
Combretastatin A4

scholarly journals Nanotechnology in metastatic cancer treatment: Current Achievements and Future Research Trends

2019 ◽  
Vol 10 (6) ◽  
pp. 1358-1369 ◽  
Author(s):  
Diana Gonciar ◽  
Teodora Mocan ◽  
Cristian Tudor Matea ◽  
Claudiu Zdrehus ◽  
Ofelia Mosteanu ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Metastatic Cancer ◽  
Research Trends ◽  
Future Research

Patient’s insurance status impact on biomarker testing in the United States market.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18114-e18114
Author(s):  
Daniel F. Winkelman ◽  
Amir Forouzan ◽  
Mike Lavin ◽  
Tanuja Tangudu ◽  
Kristopher Custer ◽  
...  
Keyword(s):  
United States ◽  
Cancer Treatment ◽  
Targeted Therapies ◽  
Point Of Care ◽  
Metastatic Cancer ◽  
The United States ◽  
Baseline Measure ◽  
Data Set ◽  
Insurance Type ◽  
Biomarker Testing

e18114 Background: Precision medicine in cancer treatment is driven by biomarker testing. If a patient is not biomarker tested, he or she may not receive access to targeted therapies that often offer greater efficacy. The purpose of this research study is to examine the insurance type of patients that are untested for biomarkers in the United States. Methods: BrandImpact is a longitudinal panel of 450 Oncologists who continuously report cancer treatment decisions from the point-of-care. The BrandImpact data set includes 60,465 patient visits reported in 2018. This study followed market research best practices. This research included visits by patients diagnosed with metastatic: NSCLC, melanoma and ovarian cancer who were either tested or untested for the following biomarkers: EGFR, ALK, ROS1, PD-L1, BRAF and BRCA. Results: The baseline measure for this analysis is that 18% of the patient visits reported that were not biomarker tested. The table at the end of document outlines the untested patient visits by insurance type for comparison purposes. Conclusions: The rate of biomarker testing for metastatic cancer patients treated by Oncologists differs by insurance type. Patients with Medicare Only insurance (25%) are untested at a statistically significantly higher rate than the baseline All category. It should be noted that patients without insurance or who were cash-paying had the highest rates of being non-biomarker tested. It is recommended that further research be conducted into the reasons behind the significantly higher rate of non-testing for Medicare Only patients. It seems counter intuitive that this patient population is treated less than optimally due to limited access to targeted therapies. [Table: see text]

Polymer–Drug Nanoparticles Combine Doxorubicin Carrier and Heparin Bioactivity Functionalities for Primary and Metastatic Cancer Treatment

2017 ◽  
Vol 14 (2) ◽  
pp. 513-522 ◽  
Author(s):  
Ling Mei ◽  
Yayuan Liu ◽  
Chunyu Xia ◽  
Yubei Zhou ◽  
Zhirong Zhang ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Metastatic Cancer ◽  
Drug Nanoparticles

Resistance to Intervention: Paclitaxel in Breast Cancer

2020 ◽  
Vol 20 ◽  
Author(s):  
Vipin Mohan Dan ◽  
Reji Saradha Raveendran ◽  
Sabulal Baby
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Patient Outcomes ◽  
Clinical Management ◽  
Drug Targets ◽  
Metastatic Cancer ◽  
Resistance Mechanisms ◽  
Breast Cancer Treatment ◽  
Regulatory Proteins ◽  
Oriented Research

Abstract:: Breast cancer stands as the most prevalent cancer in women globally, and contributes to highest percentage in mortality to cancer related deaths in women. Paclitaxel (PTX) is heavily relied on as a frontline chemotherapy in breast cancer treatment, especially in advanced metastatic cancer. Generation of resistance to PTX often derails clinical management and adversely affects patient outcomes. Defining the molecular mechanism underlying PTX resistance is mostly sought for to aid in overcoming resistance, and this oriented research has led to the understanding of a range of PTX resistance related therapeutic targets. PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets. This resistance related targets can be dealt with synthetic/natural therapeutics in combination with PTX. The present review encompasses recent understanding of PTX resistance mechanisms in breast cancer and possible therapeutic combinations to overcome resistance.

Dying from cancer

2018 ◽  
Author(s):  
Martin Scott-Brown
Keyword(s):  
Quality Of Life ◽  
Cancer Treatment ◽  
Advanced Cancer ◽  
Metastatic Cancer ◽  
Obstructive Uropathy ◽  
Poor Quality ◽  
Best Interest ◽  
Patient’S Perception ◽  
Acute Event

For many patients, dying from cancer has been an ever-present reality from the time they were diagnosed with incurable recurrent or metastatic cancer. Treatment may have delayed the inevitable, but there does come a point where aggressive management no longer improves the prognosis or can only prolong life that is of such a poor quality that it is not valued by the patient. It sometimes is easier to continue with treatment than to take the time with the patient to discuss the reasons why further treatment is not appropriate. For patients with advanced cancer and whose condition is deteriorating, a number of questions should be considered before initiating treatment aimed at prolonging life. Is this the final stage of a progressive deterioration or an acute event? Are the causes of this deterioration reversible? Are there any further oncological treatments that may improve the prognosis? What is the patient’s perception of their quality of life? Is there a realistic chance of return to a quality of life that will be of value to the patient? Is the patient dying? The ICU is usually not appropriate for patients with advanced cancer. Treatment of correctable causes (e.g. obstructive uropathy, chest infection) may still not be in the patient’s best interest if they recover only to face a period of further deterioration and distressing symptoms before they die. However, patients and their families must be included in discussions as to the level of further intervention and the reasons for stopping active treatment.

Sign in / Sign up

Export Citation Format

Share Document